Skip to main content
. 2006 Apr 19;26(16):4383–4393. doi: 10.1523/JNEUROSCI.4531-05.2006

Figure 6.

Figure 6.

HPGDS-inhibitor alleviated astrogliosis via inhibition of DP1 upregulation in GALCtwi/twi. GALCtwi/twi received a daily subcutaneous injection of 50 mg · kg−1 · d−1 HQL-79 from P25 to P45. As a control, the same volume of vehicle was injected into GALCtwi/twi during the same period. A–C, Vehicle-treated GALCtwi/twi. D–F, HQL-79-treated GALCtwi/twi. A, B, D, E, GFAP immunostaining. C, F, DP1 immunostaining. Scale bar, 50 μm. G, Quantitative RT-PCR (top) and Northern blot analyses (bottom) for vehicle-treated and HQL-79-treated GALCtwi/twi. n = 3. *p < 0.05. CGL, Cerebellar granular layer; CML, cerebellar molecular layer.